Author: claimsbot

1. A headlight for a motor vehicle having a light source, which is arranged in a reflector, for emission of light beams in a light outlet direction, the headlight comprising:
a masking apparatus which has a mask which is movable to a first position in order to mask out at least a portion of the light beams, and which is movable to a second position in which the mask is moved at least partially out of the light beams,
an actuator unit for producing the movement of the mask, which has at least one magnet coil and a magnet yoke in order to form a magnetic flux circuit,
a hinged armature retained in an articulated manner on at least a part of the magnet yoke and is in the form of part of the mask, such that the hinged armature carries out a folding movement, and produces the movement of the mask, when current is passed through the magnet coil,
a magnet core that extends at least partially through the magnet coil, wherein, when current is passed through the magnet coil, the hinged armature is drawn against andor in the direction of the magnet core and the hinged armature becomes a component of the magnetic flux circuit, and
an opposing armature, which is located in the magnetic flux, is seated on the end of the magnet core on the hinged armature side and has a force flow edge which extends parallel to an opposing edge which is formed on the hinged armature.
2. The headlight according to claim 1, wherein the movement of the mask corresponds to a rotary movement about a hinge axis, wherein the hinge axis is arranged in the light outlet direction, and wherein the first position of the mask is a dimmed light position, and the second position of the mask is a main beam position.
3. The headlight according to claim 2, wherein the articulated retention of the hinged armature on the magnet yoke is formed by a hinge arrangement, through which the magnetic flux passes between the magnet yoke and the hinged armature.
4. The headlight according to claim 1, wherein the articulated retention of the hinged armature on the magnet yoke is formed by a hinge arrangement, through which the magnetic flux passes between the magnet yoke and the hinged armature.
5. The headlight according to claim 1, wherein the mask is formed from at least one mask arm and the hinged armature, wherein the hinged armature is in the form of a plate and extends on a plane at right angles to the extent plane of the mask arm of the mask.
6. The headlight according to claim 5, wherein the mask has a compensating mass which is in the form of a plate and extends on a plane at right angles to the hinged armature and at right angles to the mask arm.
7. The headlight according to claim 1 further comprising a spring element arranged between the magnet yoke and the hinged armature, the spring element is in the form of a spring clip and applies force to the hinged armature such that it is held in a folded position, which corresponds to a dimmed light position of the mask, when no current is passed through the magnet coil.
8. The headlight according to claim 1, further comprising a spring element in the form of a tension spring or a compression spring, and extends between the hinged armature and the magnet yoke.
9. The headlight according to claim 1, wherein the magnet core has a widened area in the form of a plate with a cylindrical attachment which extends in the direction of the hinged armature from the magnet coil, wherein the hinged armature has a cutout into which the cylindrical attachment extends.
10. The headlight according to claim 9, wherein a hinge arrangement between the magnet yoke and the hinged armature has a curved cutout in the connection area to the magnet yoke, in which a rolling surface of the hinged armature is held, which rolls along the curved cutout during movement of the hinged armature, such that a gap which exists between the cylindrical attachment of the magnet core and the cutout of the hinged armature remains essentially unchanged over the movement of the hinged armature.
11. The headlight according to claim 1, wherein the opposing armature is in the form of a planar body and extends on a plane which extends at right angles to the magnet coil, wherein a holding carriage is provided, which holds the opposing armature such that it cannot move and on which the hinged armature is arranged via a hinge arrangement, such that it can move.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method for automatically controlling a stationary gaseous fueled engine, comprising the steps of:
computing an engine speed control deviation (dn) from a set engine speed (nSL) and an actual engine speed (nIST);
determining a set torque (MSL) as a correcting variable from the speed control deviation (dn) by a speed controller;
determining a set volume flow (VSL) as a function of the set torque (MSL) to establish a mixture throttle angle (DKWI, DKW2) and a gaseous fuel throttle angle;
varying the set volume flow (VSL) to adjust the gaseous fuel throttle angle by a correction factor (k); and
computing the correction factor (k) using a volume correction unit as a function of an actual system output (PAIST) and a limited set torque (MSLB), which is computed by a torque limiter from the set torque (MSL), including converting the actual system output (PAIST) to an actual system torque (MAIST), computing a quotient (Q(i)) from the actual system torque (MAIST) and the limited set torque (MSLB), and determining the correction factor (k) from the quotient (Q(i)) using an I controller.
2. The method in accordance with claim 1, including computing a mean value (MW) from the quotients (Q(i), i=1, 2, 3, . . . ) within a computation interval, and determining the correction factor (k) with the I controller based on the mean value (MW).
3. The method in accordance with claim 2, including limiting the correction factor (k).
4. The method in accordance with claim 1, wherein, in a steady-state operating condition, the correction factor (k) is set as the current value for the correction of the set volume flow (VSL), and in a non-steady-state operating condition, the last correction factor (k) determined during a steady-state operating condition is kept as the current value for the correction of the set volume flow (VSL).

What is claimed is:

1. An isolated polypeptide selected from the group consisting of:
a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-26,
b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-26,
c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-26, and
d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-26.
2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-26.
3. An isolated polynucleotide encoding a polypeptide of claim 1.
4. An isolated polynucleotide encoding a polypeptide of claim 2.
5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:27-52.
6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
7. A cell transformed with a recombinant polynucleotide of claim 6.
8. A transgenic organism comprising a recombinant polynucleotide of claim 6.
9. A method of producing a polypeptide of claim 1, the method comprising:
a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
b) recovering the polypeptide so expressed.
10. A method of claim 9, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-26.
11. An isolated antibody which specifically binds to a polypeptide of claim 1.
12. An isolated polynucleotide selected from the group consisting of:
a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:27-52,
b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:27-52,
c) a polynucleotide complementary to a polynucleotide of a),
d) a polynucleotide complementary to a polynucleotide of b), and
e) an RNA equivalent of a)-d).
13. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 12.
14. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:
a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
15. A method of claim 14, wherein the probe comprises at least 60 contiguous nucleotides.
16. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:
a) amplify said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
17. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.
18. A composition of claim 17, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-26.
19. A method for treating a disease or condition associated with decreased expression of functional TRICH, comprising administering to a patient in need of such treatment the composition of claim 17.
20. A method of screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
b) detecting agonist activity in the sample.
21. A composition comprising an agonist compound identified by a method of claim 20 and a pharmaceutically acceptable excipient.
22. A method for treating a disease or condition associated with decreased expression of functional TRICH, comprising administering to a patient in need of such treatment a composition of claim 21.
23. A method of screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
b) detecting antagonist activity in the sample.
24. A composition comprising an antagonist compound identified by a method of claim 23 and a pharmaceutically acceptable excipient.
25. A method for treating a disease or condition associated with overexpression of functional TRICH, comprising administering to a patient in need of such treatment a composition of claim 24.
26. A method of screening for a compound that specifically binds to the polypeptide of claim 1, the method comprising:
a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.
27. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, the method comprising:
a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.
28. A method of screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:
a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
b) detecting altered expression of the target polynucleotide, and
c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
29. A method of assessing toxicity of a test compound, the method comprising:
a) treating a biological sample containing nucleic acids with the test compound,
b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 12 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 12 or fragment thereof,
c) quantifying the amount of hybridization complex, and
d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
30. A diagnostic test for a condition or disease associated with the expression of TRICH in a biological sample, the method comprising:
a) combining the biological sample, with an antibody of claim 11, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex, and
b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.
31. The antibody of claim 11, wherein the antibody is:
a) a chimeric antibody,
b) a single chain antibody,
c) a Fab fragment,
d) a F(ab)2 fragment, or
e) a humanized antibody.
32. A composition comprising an antibody of claim 11 and an acceptable excipient.
33. A method of diagnosing a condition or disease associated with the expression of TRICH in a subject, comprising administering to said subject an effective amount of the composition of claim 32.
34. A composition of claim 32, wherein the antibody is labeled.
35. A method of diagnosing a condition or disease associated with the expression of TRICH in a subject, comprising administering to said subject an effective amount of the composition of claim 34.
36. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11, the method comprising:
a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-26, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
b) isolating antibodies from said animal, and
c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-26.
37. A polyclonal antibody produced by a method of claim 36.
38. A composition comprising the polyclonal antibody of claim 37 and a suitable carrier.
39. A method of making a monoclonal antibody with the specificity of the antibody of claim 11, the method comprising:
a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-26, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
b) isolating antibody producing cells from the animal,
c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells,
d) culturing the hybridoma cells, and
e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-26.
40. A monoclonal antibody produced by a method of claim 39.
41. A composition comprising the monoclonal antibody of claim 40 and a suitable carrier.
42. The antibody of claim 11, wherein the antibody is produced by screening a Fab expression library.
43. The antibody of claim 11, wherein the antibody is produced by screening a recombinant inmunoglobulin library.
44. A method of detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-26 in a sample, the method comprising:
a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-26 in the sample.
45. A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-26 from a sample, the method comprising:
a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-26.
46. A microarray wherein at least one element of the microarray is a polynucleotide of claim 13.
47. A method of generating a transcript image of a sample which contains polynucleotides, the method comprising:
a) labeling the polynucleotides of the sample,
b) contacting the elements of the microarray of claim 46 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and
c) quantifying the expression of the polynucleotides in the sample.
48. An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, and wherein said target polynucleotide is a polynucleotide of claim 12.
49. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.
50. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.
51. An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to said target polynucleotide.
52. An array of claim 48, which is a microarray.
53. An array of claim 48, further comprising said target polynucleotide hybridized to a nucleotide molecule comprising said first oligonucleotide or polynucleotide sequence.
54. An array of claim 48, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.
55. An array of claim 48, wherein each distinct physical location on the substrate contains multiple nucleotide molecules, and the multiple nucleotide molecules at any single distinct physical location have the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another distinct physical location on the substrate.
56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.
57. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.
58. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.
59. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.
60. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.
61. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.
62. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.
63. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.
64. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.
65. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.
66. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:11.
67. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:12.
68. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.
69. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.
70. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:15.
71. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:16.
72. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:17.
73. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:18.
74. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:19.
75. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:20.
76. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:21.
77. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:22.
78. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:23.
79. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:24.
80. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:25.
81. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:26.
82. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:27.
83. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:28.
84. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:29.
85. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:30.
86. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:31.
87. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:32.
88. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:33.
89. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:34.
90. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:35.
91. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:36.
92. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:37.
93. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:38.
94. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:39.
95. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:40.
96. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:41.
97. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:42.
98. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:43.
99. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:44.
100. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:45.
101. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:46.
102. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:47.
103. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:48.
104. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:49.
105. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:50.
106. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:51.
107. A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:52.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An optical fiber connector, comprising:
a housing comprising a first sidewall and an opposite second sidewall;
a connector body received in the housing adjacent to the second sidewall;
a plurality of optical fibers attached to the connector body and extending through the first sidewall; and
a spring portion received in the housing and resiliently compressed between the connector body and the first sidewall, the spring portion comprising two U shaped spring members.
2. The optical fiber connector of claim 1, wherein the second sidewall defines an opening for allowing insertion of the connector body into the housing.
3. The optical fiber connector of claim 2, wherein the connector body comprises a plurality of lenses exposed at the second sidewall and optically coupled to the respective optical fibers.
4. The optical fiber connector of claim 2, wherein the housing comprises two blocks formed on opposite sides of the opening, the connector body comprises two engaging portions corresponding to the two blocks, and the blocks and the engaging portions are configured to cooperatively create a snap-fit connection between the housing and the connector body.
5. The optical fiber connector of claim 1, wherein the first sidewall defines a plurality of through holes for extending the optical fibers therethrough.
6. The optical fiber connector of claim 1, wherein the spring members are integrally formed with the connector body.
7. An optical fiber connector, comprising:
a housing comprising a first sidewall and an opposite second sidewall; and
a connector body received in the housing adjacent to the second sidewall, the connector body comprising a plurality of lenses exposed at the second sidewall and optically coupled to the respective optical fibers;
a plurality of optical fibers attached to the connector body and extending through the first sidewall; and
two U shaped spring members received in the housing and resiliently compressed between the connector body and the first sidewall.
8. The optical fiber connector of claim 7, wherein the second sidewall defines an opening for allowing insertion of the connector body into enter the housing.
9. The optical fiber connector of claim 8, wherein the housing comprises two blocks formed on opposite sides of the opening, the connector body comprises two engaging portions corresponding to the two blocks, and the blocks and the engaging portions are configured to cooperatively create a snap-fit connection between the housing and the connector body.
10. The optical fiber connector of claim 7, wherein the first sidewall defines a plurality of through holes for extending the optical fiber therethrough.
11. The optical fiber connector of claim 7, wherein the resilient members are integrally formed with the connector body.
12. An optical fiber connector, comprising:
a housing comprising a first sidewall, an opposite second sidewall and an opening defined in the second sidewall;
a connector body received in the housing, the connector body having a portion extending beyond the second sidewall through the opening;
a plurality of optical fibers attached to the connector body and extending through the first sidewall; and

a spring portion received in the housing and resiliently compressed between the connector body and the first sidewall, the spring portion configured to apply a force upon the connector body in a direction from the first sidewall to the second sidewall, the spring portion comprising two U shaped spring members.